Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Brain, Body, Cognition - A continuation of Functional Neurology, Rehabilitation and Ergonomics
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Strategic Alliances in Biotechnology and Pharmaceuticals
Tell A Friend
Tell someone you know about this product.
Strategic Alliances in Biotechnology and Pharmaceuticals
Retail Price: $162.00
10% Online Discount
You Pay:

Authors: Hans Gottinger (Stratec, Munich, Germany) Celia Umali (School of Economics, Univ. of Nagasaki, Nagasaki, Japan) Frank Floether (Dr. Floether Consulting, Amden Switzerland) 
Book Description:
This book covers a strategic industry analysis of a globally operating pharmaceutical and biotechnology industry. Both biotechnology and large pharmaceutical firms compete in a network industry characterized by rapid technological change which leads to industry change and market structure. In particular, these firms depend on the creation of new knowledge. New knowledge presents particular issues regarding transferability. Innovation potentials and alliance competencies should be prevalent in any market characterized by fast changing intangible assets , given the difficulties in trading intangibles; moreover, in industries with very high rates of technology change, technologies can be introduced that create new market segments, obsolesce existing product lines, and create substantial competitors from previously little-known firms.

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.

Table of Contents:
1. Essentials for Alliance Formation (4,400 words)pp.1-14

1. 1 Introduction
1. 2 The Dilemma of Strategy
1. 3 Strategy and Transaction Cost Economics
1. 4 Corporate Governance
1. 5 The Driving Forces Behind Alliance Formation
1. 6 Dimensions of Network Formation
1. 7 Various levels of Biotech-Pharma Alliances

2. The Science and Technology Base of the Biotech Industry ( 4,500 words)pp.15-28

2. 1 Introduction
2. 2 Defining Biotechnology
2. 3 Science Evolution
2. 4 Emphasis on Molecular Biology
2. 5 Science-Technology Entrepreneurship
2. 6 University-Industrial Relationship
2. 7 The Formation of New Biotechnology Firms
2. 8 Collaborative Agreements
2. 9 Conclusions

3. Alliances in the Biotech Industry: An Industry Study of Network Economies (9,000 words)pp.29-54
3. 1 Introduction
3. 2 Biotechnology Industry and Drug Development
3.3 Network Formation Dimension

3. 4 Evolution of Alliances
3. 5 Genomics and Network Economics
3. 6 Information and Drug Discovery
3. 7 Recent Pharma and Biotech Alliances

4. Alliance Propensity of Biotech-Pharma Companies: An Empirical Perspective (6,000 words)pp.55-72
4. 1 Collaboration and Market Performance
4.2 Collaboration Rate

4.3 Some Empirical Findings

4.4 R&D and M&A

4.5 Network Dimension
4.6 Collaboration and Performance in the Pharmaceutical Industry: Seminal versus Incremental Innovation
4.7 Implications for Firm Governance
4.8 The Evolution of Firm Networks

5. European Biotech-Pharma Industry Development (6,600 words)pp.73-88
5. 1 Introduction
5. 2 Mergers and Acquisitions
5. 3 The Biotech Pharma Link: Historical Record
5. 4 Corporate Alliances
5.5 Innovation Trends
5. 6 The European Biotech Industry in Diversity
5. 7 Conclusions

6. Emerging Asian Biotech-Pharma Industry – Analysis and Trends (6,600 words)pp.89-106

6. 1 Introduction

6. 2 Fledging Asian Biotech Industry

6. 3 Innovation Capacity

6. 4 Government Initiatives in Biotechnology

6. 5 Genomics and Stem Cell Research

6. 6 Interindustry convergence: Bioinformatics and Nanomedicine

6. 7 Firm strategy in Alliance Formation

6. 8 Conclusions

7. Emerging Asian Biotech-Pharma Industry – Comparative Perspectives
(5,800 words)pp.107-136
7.1 Introduction
7.2 The Situation in Pharma
7.3 Focus Biotechnology
7.4 Intellectual Property Rights (IPO)
7.5 Clinical trials in key Asian countries
7.6 Operating Models for Big Pharma in Asia
7.7 Conclusions and Outlook

8. Strategic Alliances: Post-Analysis and Projection
(2600 words)pp.137-144

Supplement (4,800 words)
Strategic Alliances, Mergers and Acquisitions, pp. 145-164
S. 1 Introduction
S.2 Integration
S.3 Network versus Firm Specificity
S.4 Screening of Market Power
S. 5 Exclusion of Access to Alliances
S.6 Tying in Strategic Alliances
S. 7 Cross Licensing
S. 8 Vertical Integration
S. 9 International Conflicts
S. 10 Conclusions

      Biotechnology in Agriculture, Industry and Medicine
   Binding: Hardcover
   Pub. Date: 2011 - 2nd quarter
   Pages: pp.173
   ISBN: 978-1-60876-997-1
   Status: AV
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Strategic Alliances in Biotechnology and Pharmaceuticals